{"transactions":[{"id":3657230,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T21:02:21.000Z","date":"2018-07-16","kind":"other","acquired":true,"shares":25074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\") is a limited partner."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG."}],"balance_after":4352295,"source":{"system":"sec-edgar","filing":"0000925421-19-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000049/edgar.xml","form_type":"5"}},{"id":3657229,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T21:02:21.000Z","date":"2018-06-18","kind":"other","acquired":true,"shares":25074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\") is a limited partner."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG."}],"balance_after":4327221,"source":{"system":"sec-edgar","filing":"0000925421-19-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000049/edgar.xml","form_type":"5"}},{"id":3657228,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T21:02:21.000Z","date":"2018-05-16","kind":"other","acquired":true,"shares":25074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\") is a limited partner."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG."}],"balance_after":4302147,"source":{"system":"sec-edgar","filing":"0000925421-19-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000049/edgar.xml","form_type":"5"}},{"id":3958741,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2018-04-23T20:43:23.000Z","date":"2018-04-23","kind":"exercise","acquired":false,"shares":5214286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The 5,214,286 shares of Series A-1 Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 909,090 shares of the Issuer's Common Stock without payment or further consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The 5,214,286 shares of Series A-1 Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 909,090 shares of the Issuer's Common Stock without payment or further consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\"). NIBRI is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":909090},"source":{"system":"sec-edgar","filing":"0001104659-18-025864","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465918025864/a4.xml","form_type":"4"}},{"id":3958740,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-04-23T20:43:23.000Z","date":"2018-04-23","kind":"exercise","acquired":false,"shares":1571429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The 1,571,429 shares of Series A Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 2,272,726 shares of the Issuer's Common Stock without payment or further consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The 1,571,429 shares of Series A Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 2,272,726 shares of the Issuer's Common Stock without payment or further consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\"). NIBRI is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2272726},"source":{"system":"sec-edgar","filing":"0001104659-18-025864","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465918025864/a4.xml","form_type":"4"}},{"id":3958739,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T20:43:23.000Z","date":"2018-04-23","kind":"purchase","acquired":true,"shares":766666,"price":15,"value":11499990.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\"). NIBRI is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG."}],"balance_after":3948482,"source":{"system":"sec-edgar","filing":"0001104659-18-025864","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465918025864/a4.xml","form_type":"4"}},{"id":3958738,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T20:43:23.000Z","date":"2018-04-23","kind":"exercise","acquired":true,"shares":909090,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The 5,214,286 shares of Series A-1 Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 909,090 shares of the Issuer's Common Stock without payment or further consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\"). NIBRI is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG."}],"balance_after":3181816,"source":{"system":"sec-edgar","filing":"0001104659-18-025864","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465918025864/a4.xml","form_type":"4"}},{"id":3958737,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T20:43:23.000Z","date":"2018-04-23","kind":"exercise","acquired":true,"shares":2272726,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The 1,571,429 shares of Series A Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 2,272,726 shares of the Issuer's Common Stock without payment or further consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\"). NIBRI is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG."}],"balance_after":2272726,"source":{"system":"sec-edgar","filing":"0001104659-18-025864","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465918025864/a4.xml","form_type":"4"}},{"id":3970319,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-04-04T20:24:36.000Z","date":"2018-04-02","kind":"exercise","acquired":false,"shares":1979226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1979226},"source":{"system":"sec-edgar","filing":"0000899243-18-009444","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000089924318009444/doc4.xml","form_type":"4"}},{"id":3970318,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-04T20:24:36.000Z","date":"2018-04-02","kind":"exercise","acquired":true,"shares":1979226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Common Stock held directly by NIBRI."}],"balance_after":1979226,"source":{"system":"sec-edgar","filing":"0000899243-18-009444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000089924318009444/doc4.xml","form_type":"4"}},{"id":4131985,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T17:19:19.000Z","date":"2017-12-12","kind":"sale","acquired":false,"shares":1523000,"price":18.3,"value":27870900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is exclusive of any fees, commissions or other expenses."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG."}],"balance_after":4129903,"source":{"system":"sec-edgar","filing":"0001104659-17-073312","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465917073312/a4.xml","form_type":"4"}},{"id":4397873,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-07T20:11:18.000Z","date":"2017-03-03","kind":"other","acquired":true,"shares":79245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\") is a limited partner."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG."}],"balance_after":5652903,"source":{"system":"sec-edgar","filing":"0001209191-17-018679","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000120919117018679/doc4.xml","form_type":"4"}}]}